Biogen Idec Inc., maker of the multiple sclerosis drugs Avonex, Tysabri, and Tecfidera, boosted its 2013 forecast after Tecfidera sales topped estimates. Revenue this year will grow 23 to 25 percent, with adjusted earnings of $8.65 to $8.85 a share. It had projected revenue gaining 22 to 23 percent and earnings of $8.25 to $8.50. Quarterly Tecfidera sales of $286.4 million beat analysts’ average $217.2 million estimate. ‘‘Tecfidera crushed it,’’ wrote Mark Schoenebaum, at ISI Group. ‘‘This is really, truly, incredible.’’ Revenue rose 32 percent to $1.83 billion. Net income increased 22 percent to $487.6 million.
Mass. Movers